Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Kochevar

Plastic and Reconstructive Surgery Springfield, MO Medical Doctor

NPI 1871781765 CMS profile 815081

1229 E Seminole St Ste 340, Springfield, MO 65804

Open in the dashboard

General payments

$2,835

45 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Kochevar of Springfield, MO is reported in the CMS Open Payments database as having received $2,835 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $928 10
2024 General $646 12
2023 General $638 5
2022 General $203 6
2021 General $189 5
2020 General $128 4
2019 General $105 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Kochevar
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Andrew Kochevar were reported at $928. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Andrew Kochevar Plastic and Reconstructive Surgery median Middle half National median
2019 $105 $335 $121–$1,264 $163
2020 $128 $162 $57–$417 $114
2021 $189 $245 $89–$735 $132
2022 $203 $325 $120–$932 $149
2023 $638 $343 $129–$999 $160
2024 $646 $390 $141–$1,085 $164
2025 $928 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Integra LifeSciences Corporation $1,670 15 payments
  2. Lumenis BE inc $360 1 payment
  3. Mentor Worldwide LLC $157 11 payments
  4. Allergan Inc. $140 4 payments
  5. DePuy Synthes Sales Inc. $89 1 payment
  6. AbbVie, Inc. $83 3 payments
  7. Stryker Corporation $75 1 payment
  8. Biocomposites Inc $70 1 payment
  9. PolyNovo North America LLC $42 1 payment
  10. Vertex Pharmaceuticals Incorporated $41 2 payments
  11. Other $108 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,010 41 payments
  2. Long term medical supply or device loan $826 4 payments
Products named General payments · program years 2019–2025
  1. Integra Recon-Skin And Wound $1,165 11 payments
  2. INTEGRA DERMAL REGENERATION TEMPLATE $845 11 payments
  3. PRIMATRIX $845 11 payments
  4. Integra Recon-Skin And Wound $705 9 payments
  5. Integra Recon-Skin And Wound $705 9 payments
  6. M22 $360 1 payment
  7. AMNIOEXCEL $199 1 payment
  8. Cytal $166 1 payment
  9. INTEGRA WOUND MATRIX (THIN) $139 2 payments
  10. INTEGRA MESHED BILAYER WOUND MATRIX $139 2 payments
  11. Other $1,029 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

310

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$4,115

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

31.6%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enoxaparin Sodium Generic 13 $1,817
Oxycodone Hcl Generic 103 $668
Erythromycin Erythromycin Base Brand 50 $514
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 16 $507
Cephalexin Generic 81 $254
Ondansetron Odt Ondansetron Brand 20 $193
Clindamycin Hcl Generic 15 $96
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$51,450

Medicare's payments for the services billed

Medicare patients

108

Average age 72

Services billed

289

72 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 40%
Cancer 35%
Depression 31%
Chronic kidney disease 29%
Atrial fibrillation 25%
Ischemic heart disease 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record